Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 18:13:1171813.
doi: 10.3389/fonc.2023.1171813. eCollection 2023.

CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer

Affiliations

CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer

Juan Wang et al. Front Oncol. .

Abstract

Background: The treatment of local-regional recurrent breast cancer (BC) after external beam radiotherapy is challenging. We aim to evaluate the effectiveness and safety of computed tomography (CT)-guided percutaneous iodine-125 brachytherapy for local recurrent BC.

Methods: We retrospectively analyzed 15 patients with local recurrent BC treated with CT-guided interstitial implantation of iodine-125 seeds. Regular contrast-enhanced CT was conducted to evaluate the tumor response. Follow-up survival, quality of life, and adverse events were analyzed.

Results: Among the 15 patients, five were elderly patients (older than 80 years) and six were complicated with chronic underlying diseases. The median number of 125I seeds implantation was 33 (range: 20-130) with median dose 90 (D90, the minimum dose covering 90% of the target volume) of 108 Gy (range: 60-120 Gy). There was no significant difference in D90, V100 (the volume of the target receiving 100% of the prescription dose), and V150 (the volume of the target receiving 150% of the prescription dose) before and after operation (p > 0.05). The median follow-up was 14 months (range: 6-18 months). Six months after operation, the ORR was 66.7% (10/15) and the LCR was 93.3% (14/15). The 6- and 12-month survival rates were 100 and 41.6%, respectively, and the median survival time was 12.5 months. PS score decreased from 1.53 ± 0.81 to 0.53 ± 0.49. The pain score decreased from 2.87 ± 1.67 before operation to 1.07 ± 1.18 after operation, and the differences were statistically significant (p< 0.05). No severe complications occurred.

Conclusions: CT-guided iodine-125 brachytherapy provided a safe and effective choice for recurrent BC with significant local therapeutic effects and minor complications, especially for elderly patients with chronic underlying disease and those who were not eligible for surgical resection and had failed to benefit from systemic therapy.

Keywords: brachytherapy; breast cancer; computed tomography guidance; iodine-125 seed; recurrence; salvage therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) An 89-year-old woman with the chest wall lesion recurred from right BC was accurately inserted into the tumor to implant 125I seeds. (a) Pre-brachytherapy; (b) 3 months after brachytherapy, tumor shrinked; (c) 5 months after brachytherapy, tumor disappeared; (d) 9 months after brachytherapy, no recurrence. (B) An 82-year-old woman with the chest wall lesion recurred from right BC. (e) Pre-brachytherapy; (f) 1 month after brachytherapy, tumor shrinked; (g) 11 months after brachytherapy, tumor disappeared; (h) 15 months after brachytherapy, no recurrence.
Figure 2
Figure 2
The survival rate of BC patients.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. . Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) (2022) 135(5):584–590. doi: 10.1097/CM9.0000000000002108 - DOI - PMC - PubMed
    1. Speers C, Pierce LJ. Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: A review. JAMA Oncol (2016) 2(8):1075–82. doi: 10.1001/jamaoncol.2015.5805 - DOI - PubMed
    1. Liu B, Huang H, Pan L, Ma Y. Value analysis of neoadjuvant radiotherapy for breast cancer after modified radical mastectomy based on data mining. Comput Intell Neurosci (2022) 2022:6257536. doi: 10.1155/2022/6257536 - DOI - PMC - PubMed
    1. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. . Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst (2005) 97(2):116–26. doi: 10.1093/jnci/djh297 - DOI - PubMed

LinkOut - more resources